Pendahuluan: Tesis ini bertujuan untuk mengetahui efek myelosupresi pada
pasien kanker ovarium dengan kemoterapi ajuvan carboplatin dan paclitaxel di
RSUPN dr. Cipto Mangunkusumo melalui analisis kadar hemoglobin, leukosit,
dan trombosit. Kemoterapi ajuvan kombinasi carboplatin dan paclitaxel
merupakan rejimen kemoterapi yang paling efektif pada kanker ovarium. Namun
pemberian kemoterapi tersebut memiliki efek samping myelosupresi seperti
anemia, neutropenia, dan trombositopenia yang berdampak besar terhadap
kualitas hidup pasien.
Metode: Penelitian ini adalah penelitian hystorical cohort yang dilaksanakan di
RSUPN Dr. Cipto Mangunkusumo dengan mengambil sampel penelitian pasien
kanker ovarium yang mendapatkan kemoterapi ajuvan dengan carboplatin dan
paclitaxel sebanyak enam seri mulai dari Januari 2010 sampai dengan Desember
2014.
Hasil: Dari 41 subjek penelitian yang memenuhi kriteria inklusi didapatkan usia
pasien berkisar antara 25 sampai dengan 64 tahun (median: 49 tahun), terbanyak
adalah multipara (43,9%), premenopause (61,0%), dengan stadium terbanyak
adalah stadium IIIC (58,5%), histopatologi terbanyak adalah kistadenokarsinoma
serosum (39,0%), dan sebagian besar berdiferensiasi sedang (48,8%).
Kesimpulan: Sebagai kesimpulan didapatkan penurunan kadar hemoglobin, leukosit, dan trombosit yang bermakna pasca kemoterapi setiap seri (p < 0,001). ;Background: The objective of this study was to obtain the myelosupression
effect on ovarian cancer patient with carboplatin and paclitaxel adjuvant
chemotherapy based on haemoglobin, leucocyte, and thrombocyte level.
Carboplatin and paclitaxel combination as an adjuvant chemotherapy is the most
effective regiment for ovarian cancer. Otherwise this regiment has
myelosuppression effect (hematologic toxicity) as anemia, neutropenia, and
thrombocytopenia which have impact on quality of life of the patients.
Methods: This is an hystorycal cohort study on ovarian caner patients who
underwent six series of adjuvant chemotherapy from January 2010 until
December 2014 at RSUPN Dr. Cipto Mangunkusumo.
Results: From 41 patients range at 25 until 64 years old (median: 49 years), most
of them are multiparity (43,9%), premenopausal women (61,0%), with the largest
stadium was IIIC (58,5%), the largest pathologic type was serous
cystadenocarcinoma (39,0%) and most of them are intermediate differentiation
(48,8%).
Conclusions: As a conclusion there was a significantly decreased of haemoglobin, leucocyte, and thrombocyte levels after adjuvant chemotherapy on every single cycle (p<0,001). ;Background: The objective of this study was to obtain the myelosupression
effect on ovarian cancer patient with carboplatin and paclitaxel adjuvant
chemotherapy based on haemoglobin, leucocyte, and thrombocyte level.
Carboplatin and paclitaxel combination as an adjuvant chemotherapy is the most
effective regiment for ovarian cancer. Otherwise this regiment has
myelosuppression effect (hematologic toxicity) as anemia, neutropenia, and
thrombocytopenia which have impact on quality of life of the patients.
Methods: This is an hystorycal cohort study on ovarian caner patients who
underwent six series of adjuvant chemotherapy from January 2010 until
December 2014 at RSUPN Dr. Cipto Mangunkusumo.
Results: From 41 patients range at 25 until 64 years old (median: 49 years), most
of them are multiparity (43,9%), premenopausal women (61,0%), with the largest
stadium was IIIC (58,5%), the largest pathologic type was serous
cystadenocarcinoma (39,0%) and most of them are intermediate differentiation
(48,8%).
Conclusions: As a conclusion there was a significantly decreased of haemoglobin, leucocyte, and thrombocyte levels after adjuvant chemotherapy on every single cycle (p<0,001).
SP-Better Versi Paniroi.pdf :: Unduh